%0 Journal Article
%A Karschnia, Philipp
%A Young, Jacob S
%A Wijnenga, Maarten M J
%A Sciortino, Tommaso
%A Teske, Nico
%A Corell, Alba
%A Wagner, Arthur
%A Youssef, Gilbert
%A Park, Yae Won
%A Häni, Levin
%A Jünger, Stephanie T
%A Dono, Antonio
%A Ehret, Felix
%A Mireles, Eduardo E Mendoza
%A Neidert, Nicolas
%A Bruno, Francesco
%A Tuchek, Chad A
%A van der Vaart, Thijs
%A Rossi, Marco
%A Nibali, Marco Conti
%A Gay, Lorenzo
%A Gramelt, Alfred
%A Tandon, Nitin
%A Ahn, Sung Soo
%A Chang, Jong Hee
%A Weller, Michael
%A Vincent, Arnaud J P E
%A Goldbrunner, Roland
%A Cahill, Daniel P
%A Huang, Raymond Y
%A Raabe, Andreas
%A Meyer, Bernhard
%A Beck, Juergen
%A Molinaro, Annette M
%A Chang, Susan M
%A Vogelbaum, Michael A
%A Rudà, Roberta
%A Vik-Mo, Einar O
%A Dietrich, Jorg
%A Esquenazi, Yoshua
%A Grau, Stefan J
%A Wen, Patrick Y
%A Jakola, Asgeir S
%A Schnell, Oliver
%A Bello, Lorenzo
%A van den Bent, Martin J
%A Hervey-Jumper, Shawn
%A Berger, Mitchel S
%A Tonn, Joerg-Christian
%T A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group.
%J The lancet / Oncology
%V 26
%N 12
%@ 1470-2045
%C London
%I The Lancet Publ. Group
%M DKFZ-2025-02642
%P 1638 - 1650
%D 2025
%X The efficacy of resection in IDH-mutant grade 2 gliomas remain controversial since terminology for the extent of resection has been inconsistently applied across studies. We aimed to establish a standardised classification for the extent of resection and assess the association between supramaximal resection and survival across molecular subtypes.In this international, multicentre, retrospective study, patients aged 18 years and older with newly diagnosed grade 2 IDH-mutant glioma were identified from institutional databases across 16 centres in the USA, Europe, and Asia between between Sept 1, 1993, and May 10, 2024. We used Cox proportional hazard regressions to analyse the associations between residual tumour and progression-free survival and overall survival. Patients were stratified according to a previously postulated classification system based on residual tumour volume. A cohort of patients from UCSF diagnosed between Feb 16, 1998, and Nov 14, 2017, was used for geographically and institutionally independent external validation.We identified 1391 patients with newly diagnosed IDH-mutant grade 2 gliomas, with a median follow-up of 81 months (95
%K Humans
%K Middle Aged
%K Female
%K Isocitrate Dehydrogenase: genetics
%K Male
%K Retrospective Studies
%K Adult
%K Brain Neoplasms: surgery
%K Brain Neoplasms: genetics
%K Brain Neoplasms: pathology
%K Brain Neoplasms: mortality
%K Brain Neoplasms: classification
%K Mutation
%K Glioma: surgery
%K Glioma: genetics
%K Glioma: pathology
%K Glioma: mortality
%K Prognosis
%K Neoplasm Grading
%K Aged
%K Progression-Free Survival
%K Young Adult
%K Neurosurgical Procedures: mortality
%K Neoplasm, Residual
%K Isocitrate Dehydrogenase (NLM Chemicals)
%K IDH2 protein, human (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41308678
%R 10.1016/S1470-2045(25)00534-0
%U https://inrepo02.dkfz.de/record/306605